PCI Biotech (Norway) Market Value
| PCIB Stock | NOK 1.45 0.19 11.59% |
| Symbol | PCI |
PCI Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to PCI Biotech's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of PCI Biotech.
| 06/08/2023 |
| 11/29/2024 |
If you would invest 0.00 in PCI Biotech on June 8, 2023 and sell it all today you would earn a total of 0.00 from holding PCI Biotech Holding or generate 0.0% return on investment in PCI Biotech over 540 days. PCI Biotech is related to or competes with DnB ASA, Sparebank, Norsk Hydro, Equinor ASA, Aker ASA, Kongsberg Gruppen, and Telenor ASA. PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapie... More
PCI Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure PCI Biotech's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess PCI Biotech Holding upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 54.81 | |||
| Value At Risk | (8.54) | |||
| Potential Upside | 6.4 |
PCI Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for PCI Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as PCI Biotech's standard deviation. In reality, there are many statistical measures that can use PCI Biotech historical prices to predict the future PCI Biotech's volatility.| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.17) | |||
| Total Risk Alpha | (1.18) | |||
| Treynor Ratio | (0.41) |
PCI Biotech Holding Backtested Returns
PCI Biotech Holding maintains Sharpe Ratio (i.e., Efficiency) of -0.0407, which implies the company had a -0.0407% return per unit of volatility over the last 3 months. PCI Biotech Holding exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check PCI Biotech's variance of 48.36, and Market Risk Adjusted Performance of (0.40) to confirm the risk estimate we provide. The firm holds a Beta of 0.31, which implies possible diversification benefits within a given portfolio. As returns on the market increase, PCI Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding PCI Biotech is expected to be smaller as well. At this point, PCI Biotech Holding has a negative expected return of -0.28%. Please make sure to check PCI Biotech's information ratio, total risk alpha, maximum drawdown, as well as the relationship between the jensen alpha and treynor ratio , to decide if PCI Biotech Holding performance from the past will be repeated in the future.
Auto-correlation | -0.19 |
Insignificant reverse predictability
PCI Biotech Holding has insignificant reverse predictability. Overlapping area represents the amount of predictability between PCI Biotech time series from 8th of June 2023 to 4th of March 2024 and 4th of March 2024 to 29th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of PCI Biotech Holding price movement. The serial correlation of -0.19 indicates that over 19.0% of current PCI Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.19 | |
| Spearman Rank Test | 0.02 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
PCI Biotech Holding lagged returns against current returns
Autocorrelation, which is PCI Biotech stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting PCI Biotech's stock expected returns. We can calculate the autocorrelation of PCI Biotech returns to help us make a trade decision. For example, suppose you find that PCI Biotech has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
PCI Biotech regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If PCI Biotech stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if PCI Biotech stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in PCI Biotech stock over time.
Current vs Lagged Prices |
| Timeline |
PCI Biotech Lagged Returns
When evaluating PCI Biotech's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of PCI Biotech stock have on its future price. PCI Biotech autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, PCI Biotech autocorrelation shows the relationship between PCI Biotech stock current value and its past values and can show if there is a momentum factor associated with investing in PCI Biotech Holding.
Regressed Prices |
| Timeline |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in PCI Stock
PCI Biotech financial ratios help investors to determine whether PCI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PCI with respect to the benefits of owning PCI Biotech security.